Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Fineline Cube Apr 12, 2026
Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Fineline Cube Apr 12, 2026
Policy / Regulatory

China’s NHC Unveils 2024 Goals for Medical Quality and Safety Improvement

Fineline Cube Feb 2, 2024

The National Health Commission (NHC) has released the “2024 National Medical Quality and Safety Improvement...

Company

WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility

Fineline Cube Feb 1, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Deals

HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development

Fineline Cube Feb 1, 2024

HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...

Company Deals

Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...

Company Deals

Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally

Fineline Cube Feb 1, 2024

Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...

Company

Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain

Fineline Cube Feb 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...

Company Medical Device

Acotec Scientific’s Peridge Catheter Receives NMPA Nod for Hemodialysis Lesion Treatment

Fineline Cube Feb 1, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...

Company Drug

Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons

Fineline Cube Feb 1, 2024

Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has...

Company

WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry

Fineline Cube Feb 1, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...

Company

GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion

Fineline Cube Feb 1, 2024

GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...

Company

Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...

Company Drug

Gilead’s Kite Subsidiary Reduces CAR T-Cell Therapy Turnaround Time with FDA Approval

Fineline Cube Feb 1, 2024

Kite, a subsidiary of Gilead (NASDAQ: GILD), has announced a significant enhancement in the treatment...

Company Deals

Junde Pharmaceuticals Licenses Weight-Reducing Capsule JTX-102 to Changchun GeneScience

Fineline Cube Feb 1, 2024

Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing...

Company Deals

Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens

Fineline Cube Feb 1, 2024

Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing...

Company Deals

Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal

Fineline Cube Feb 1, 2024

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the...

Company Deals

Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China

Fineline Cube Feb 1, 2024

Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation...

Company Deals

MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies

Fineline Cube Feb 1, 2024

MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with...

Company Drug

Sandoz Launches Biosimilar Natalizumab in Germany, Challenging Biogen’s Tysabri

Fineline Cube Feb 1, 2024

Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in...

Company Deals R&D

Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse

Fineline Cube Jan 31, 2024

Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered...

Company

Clinigen Expands Global Footprint with First Fully-Owned Subsidiary in Shanghai’s Free Trade Zone

Fineline Cube Jan 31, 2024

Clinigen, a UK-based medical and pharmaceutical services provider, has announced the establishment of its first...

Posts pagination

1 … 388 389 390 … 648

Recent updates

  • Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease
  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
  • Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
  • Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.